The Paid-To-Hold Play On ISRG Stock: A 12% Income

Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today’s.

Intuitive Surgical (ISRG) has been a titan of medical technology, but the stock has spent the last year in a funk, trading at about $407 a share and well off its highs. For long-term owners, this kind of sideways chop can be frustrating. It also creates an opportunity to put your shares to work, generating a real cash income stream right now by agreeing to sell them at a higher price if the stock gets there. The specifics of that trade are laid out below.

12% annualized income on ISRG shares you already own, with 15% of upside room, by selling a covered call.

• You own (or buy) 100 shares of ISRG near today’s price of $407.
• Sell one call option on ISRG expiring 6/17/2027, with a strike price of $470, about 15% above today.
• Collect roughly $4,595 in premium up front per contract (each contract covers 100 shares), which you keep no matter what the stock does.
• That premium is about 12.2% annualized on the $40,712 of stock, income you earn just for holding.
• If ISRG finishes above $470, your shares are called away at $470. Counting the premium, your total return works out to about 29% annualized, but you give up any gains above the strike.

Called Away Or Not, You Pocket The Premium

If ISRG finishes below $470 on 6/17/2027, the call expires worthless, and you keep the full $4,595 premium and all your shares. That is about 11% over 339 days, income earned just for holding, and you are free to sell another call.

If ISRG finishes above $470, your 100 shares are called away at $470. You still keep the $4,595 premium, and counting it as your total gain works out to about 27%, a healthy exit. The cost of the trade is that any gain above $470 is no longer yours. And if the stock instead falls, you keep the premium but still ride the shares down, cushioned only slightly.

So the whole trade comes down to one thing: how much of that upside are you really likely to give up, and would you be content to sell at that higher price?

What Upside Would You Be Handing Over?

The only real cost is the one you have to settle in your own mind: how much blue sky are you willing to give up? The case for letting the stock run is powered by its new da Vinci platform, which is fueling impressive growth. In the last quarter, revenue jumped 23% while total procedures grew 17%, a sign the company is successfully driving what it calls “innovation-led revenue performance.” With the newer SP and Ion platforms also showing strong momentum, with procedures growing 68% and 39% respectively, there is a clear path for the stock to regain its stride. We took a closer look at the company’s growth prospects in a separate piece.

But that powerful product cycle is bumping up against some stubborn realities. Management points to “ongoing challenges in China and Japan,” two critical international markets. More concretely, the rise of GLP-1 weight-loss drugs is having a direct impact, with the company reporting that da Vinci bariatrics procedures in the U.S. “declined approximately 10%.” This isn’t a hypothetical risk; it’s a measured headwind in a key category. For investors who see these challenges limiting the stock’s near-term explosive potential, getting paid to cap your upside at a healthy gain can feel like a smart trade-off. The decision really comes down to whether you believe the new platform’s momentum can overwhelm these known drags. The one thing to watch is the company’s updated procedure growth forecast, which will tell you how management sees that balance playing out.

Find The Covered-Call Income On Your Holdings

You may not own ISRG, but you almost certainly own something that could be paying you. Our Covered Call Finder lets you type in a stock, or a few, and instantly see the income a covered call could generate on each, then dial the strike up or down with a slider to balance more income against more upside. It is the quickest way to see what the names in your own portfolio could pay.

One step out from a single name: a healthcare ETF like XLV owns the whole healthcare group at once, so no single company can sink you. It still rises and falls with that one theme, which is exactly the gap the portfolio below closes.

Pair The Premium With Real Diversification

Selling calls on a stock you own is a sensible way to manufacture income. It is still, by design, a concentrated position, and even owning a whole sector only trades single-name risk for single-theme risk. Real diversification means spreading across sectors, so one industry stumbling does not define your result.

The Trefis High Quality (HQ) Portfolio handles that: about 30 quality, cash-generative companies across sectors, chosen on the full weight of their fundamentals rather than one premium-rich setup, then sized and re-balanced with care. The payoff is a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Keep the income from trades like this, without pinning your future to any single name or theme.